,72 Immunocompromising therapies for IMIDs, such as TNF-α inhibitors, are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae and may even be associated with a lower risk of adverse COVID-19 outcomes.73 This evidence concerns the gene TNF and COVID-19.